Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

FTC’s report focused on three largest PBMs ... A transformation in the PBM space will likely lead to fairer pricing and improved access to essential medications for customers, ultimately ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...